Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

about

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Item

http://www.wikidata.org/entity/Q47159185

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@en

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@nl

type

Item

label

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@en

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@nl

prefLabel

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@en

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@nl

P1476

Cross-reactivity of antibodies ...... he JAK-STAT signaling pathway.

@en

P2093

Begoña Oliver-Martos

http://www.w3.org/2001/XMLSchema#string

Jesús Ortega-Pinazo

http://www.w3.org/2001/XMLSchema#string

Jose Luis Rodriguez-Bada

http://www.w3.org/2001/XMLSchema#string

Patricia Urbaneja

http://www.w3.org/2001/XMLSchema#string

Óscar Fernández

http://www.w3.org/2001/XMLSchema#string

P2860

Body fluid biomarkers in multiple sclerosis

The impact of thrombopoietin on clinical practice.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Evaluation of the impact of neutralizing antibodies on IFNβ response.

Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.

P2888

s41598-017-16828-x

P304

16585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-16828-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura Leyva

María Jesús Pinto Medel

Pedro J Serrano-Castro

Isaac Hurtado-Guerrero

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29185487

http://www.w3.org/2001/XMLSchema#string

P932

5707350

http://www.w3.org/2001/XMLSchema#string